{"disease":{"id":"neovascularization","name":"neovascularization"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Myopic Choroidal Neovascularization (mCNV)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"verteporfin","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."},{"drug_id":"visudyne","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Choroidal retinal neovascularization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001733","title":"Screening for Studies on Retinovascular Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT02307682","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1775,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT02434328","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1048,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT07496567","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT07440225","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT01948830","title":"Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":650,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03211741","title":"Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT01922102","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02260687","title":"Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization","phase":"","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06176352","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02484690","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01908816","title":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04439708","title":"Biomarkers and Choroidal Neovascularization","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05494775","title":"Effect of Corona Virus on Intravitreal Injections","phase":"NA","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT00511706","title":"Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":243,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04455399","title":"Time Efficiency Comparison of Two IntraVitreal Injection Techniques","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Peregrine Eye and Laser Institute","has_results":false},{"nct_id":"NCT02034006","title":"A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07002372","title":"Effect of Video Viewing on Intravitreal Injection Experience","phase":"NA","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05662943","title":"Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV","phase":"","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false},{"nct_id":"NCT03838679","title":"Imaging of the Angiofibrotic Switch in Neovascular AMD","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT02821247","title":"Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece","phase":"","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07402629","title":"Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03435926","title":"OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)","phase":"","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT04488887","title":"OCTA Metrics Repeatability and Reproducibility in Different Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT07090044","title":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Retina Research Institute, LLC","has_results":false},{"nct_id":"NCT03038880","title":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02876198","title":"Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF","phase":"","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT05659940","title":"Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.","phase":"","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT04787471","title":"Corneal Crosslinking for Treatment of Corneal Neovascularization","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Price Vision Group","has_results":false},{"nct_id":"NCT04620109","title":"Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd","has_results":false},{"nct_id":"NCT04922151","title":"601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT05011916","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06300918","title":"A Clinical Trial to Evaluate the Time Point of Anti-VEGF Pretreatment of PDR Based on Intraoperative FFA","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Jie Li","has_results":false},{"nct_id":"NCT06595355","title":"Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Isfahan University of Medical Sciences","has_results":false},{"nct_id":"NCT05969418","title":"Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT04844619","title":"KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06742307","title":"Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hospital Authority, Hong Kong","has_results":false},{"nct_id":"NCT04782271","title":"Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Sylentis, S.A.","has_results":false},{"nct_id":"NCT07187804","title":"Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Kim's Eye Hospital","has_results":false},{"nct_id":"NCT04524910","title":"A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03793400","title":"Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Changhua Christian Hospital","has_results":false},{"nct_id":"NCT02257502","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04075188","title":"Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid","phase":"NA","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","has_results":false},{"nct_id":"NCT03452527","title":"Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Iconic Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04650672","title":"Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Notal Vision Inc.","has_results":false},{"nct_id":"NCT05650047","title":"Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Notal Vision Inc.","has_results":false},{"nct_id":"NCT07298655","title":"3D Contrast Enhanced Microvascular Ultrasound of Carotid Atherosclerosis for the Detection of Carotid Plaque Neo-Revascularisation.","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"London North West Healthcare NHS Trust","has_results":false},{"nct_id":"NCT02857894","title":"Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)","phase":"","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}